Three Rounds of Stability-Guided Optimization and Systematical Evaluation of Oncolytic Peptide LTX-315

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Oncolytic peptides are emerging as potent anticancer agents.
• Improving protease stability and sustained efficacy are key challenges in oncolytic peptide development.
• LTX-315 is a first-in-class oncolytic peptide that served as a basis for optimization.

Purpose of the Study:

• To enhance the stability and anticancer efficiency of oncolytic peptides through optimization.
• To investigate the synthesis, activity, and mechanisms of novel peptide derivatives.
• To develop improved peptide-based chemotherapeutics.

Main Methods:

• Iterative optimization of the oncolytic peptide LTX-315 over three rounds.
• Synthesis and characterization of D-type peptides (e.g., FXY-12) and hybrid peptides (e.g., FXY-30).
• In vitro and in vivo evaluation of anticancer activity and mechanistic studies.

Main Results:

• D-type peptides, such as FXY-12, demonstrated significantly enhanced proteolytic stability and sustained anticancer effects.
• The novel hybrid peptide FXY-30, incorporating FXY-12 and camptothecin, exhibited superior in vitro and in vivo anticancer potency.
• FXY-30 induced rapid membranolysis and DNA double-strand breaks, leading to apoptosis.

Conclusions:

• Robust strategies were established for improving oncolytic peptide stability and therapeutic potential.
• D-type peptides offer enhanced stability and sustained anticancer efficiency.
• Hybrid peptides like FXY-30 represent a promising new class of anticancer chemotherapeutics with dual mechanisms of action.